From Nasdaq:



Editas Medicine’s stock (NASDAQ: EDIT) has declined by 83% over the past three years as it struggles to advance its clinical programs. However, Vertex Pharmaceuticals (NASDAQ: VRTX) has provided much-needed support by licensing Editas’ gene-editing technology for sickle cell disease and beta-thalassemia, potentially generating significant revenue for Editas. While this is positive news for the company and its shareholders, the stock is unlikely to be a star performer based on licensing deals alone, and investors should still consider the risks associated with investing in Editas. The collaboration with Vertex Pharmaceuticals signifies the value of Editas’s intellectual property, but the company will likely need more than licensing deals to sustain long-term success. Despite these challenges, the licensing arrangement with Vertex indicates potential for additional catalyst events and some breathing room for Editas in the coming years. However, investors should not solely rely on licensing deals to provide substantial income and should approach investing in Editas with caution.



Original: Editas Just Caught a Break Thanks to Vertex Pharmaceuticals